Compare Illinois Tool Works Inc. (ITW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs TransMedics Group Inc — how do they compare? Illinois Tool Works Inc. trades at $264.13 (market cap $74.38B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Illinois Tool Works Inc. is far larger — about 27.1× TransMedics Group Inc's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and TransMedics Group Inc for 24 Days on average.
| ITW | TMDX | |
|---|---|---|
Market Cap | $74.38B | $2.74B |
Volume | 1,125,477 | 949,331 |
Sector | Industrials | Health |
52-Week High | $299.60 | $150.42 |
52-Week Low | $241.07 | $61.99 |
Typical Hold Time | 67 Days | 24 Days |
Enterprise Value | $83.23B | $3.13B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $264.13, up 1.14% today, with a bearish technical signal but strong fundamentals including a 19.39% net income margin and three consecutive quarterly EPS beats. The stock is supported by a $1.72 quarterly dividend and a consensus price target of $276.86, though analyst ratings are mixed with 21.43% buy, 46.43% hold, and 32.14% sell. Recent news highlights its Dividend King status and institutional buying interest.
The outlook balances robust profitability and dividend reliability against technical weakness and modest revenue growth. Upside potential exists if earnings momentum continues, but risks include high valuation multiples and sector-specific headwinds. The stock presents a hold case for income-focused investors awaiting clearer technical improvement.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
